Star Broncho, 30 mg/5 ml 120 ml

Mucolytic and expectorant, is an active N-demethylated metabolite of bromhexine. It has secretomotor, secretolytic and expectorant action. It stimulates serous cells of bronchial mucosa, increases motor activity of atomizing epithelium by effect on type 2 pneumocytes in alveoli and Clara cells in bronchioles, increases formation of endogenous surfactant – surface-active substance, providing gliding of bronchial secretion in airway lumen.

Ambroxol increases the proportion of the serous component in the bronchial secretion, improving its structure and helping to reduce the viscosity and liquefy sputum; as a result, mucociliary transport is improved and expectoration of sputum from the bronchial tree is facilitated.

When ambroxol is taken orally, the effect, on average, occurs within 30 minutes and lasts for 6-12 hours, depending on the single dose.

Pharmacokinetics

Ambroxol is quickly and almost completely absorbed after oral administration. T_max is 1-3 h. Binding to plasma proteins is approximately 85%. It penetrates the placental barrier and is excreted with breast milk. Metabolized in the liver to form metabolites (dibromanthranilic acid, glucuronic conjugates), which are excreted by the kidneys. Excreted mainly by the kidneys – 90% as metabolites, less than 10% unchanged. T_1/2 from plasma is 7-12 hours. T_1/2 of ambroxol and its metabolites is approximately 22 hours.

Indications

Acute and chronic diseases of the respiratory tract, accompanied by the release of viscous sputum:

acute and chronic bronchitis;
pneumonia;
chronic obstructive pulmonary disease;
bronchial asthma with difficult sputum discharge;
bronchiectasis.

Pharmacological effect

Mucolytic and expectorant, is the active N-demethylated metabolite of bromhexine. It has secretomotor, secretolytic and expectorant effects. Stimulates serous cells of the bronchial mucosa, increases the motor activity of the ciliated epithelium by affecting type 2 pneumocytes in the alveoli and Clara cells in the bronchioles, enhances the formation of endogenous surfactant – a surfactant that ensures the sliding of bronchial secretions in the lumen of the respiratory tract.

Ambroxol increases the proportion of the serous component in the bronchial secretion, improving its structure and helping to reduce viscosity and thin the sputum; as a result, mucociliary transport improves and the removal of sputum from the bronchial tree is facilitated.

When ambroxol is taken orally, the effect, on average, occurs after 30 minutes and lasts 6-12 hours, depending on the single dose.

Pharmacokinetics

After oral administration, ambroxol is quickly and almost completely absorbed. Tmax is 1-3 hours. Plasma protein binding is approximately 85%. Penetrates the placental barrier and is excreted in breast milk. Metabolized in the liver to form metabolites (dibromanthranilic acid, glucuronic conjugates), which are excreted by the kidneys. It is excreted primarily by the kidneys – 90% in the form of metabolites, less than 10% unchanged. T1/2 from plasma is 7-12 hours. T1/2 of ambroxol and its metabolites is approximately 22 hours.

Special instructions

Ambroxol should not be taken simultaneously with antitussive drugs that can inhibit the cough reflex, for example, codeine, because this may make it difficult to remove liquefied mucus from the bronchi.

Ambroxol should be used with caution in patients with a weakened cough reflex or impaired mucociliary transport due to the possibility of sputum accumulation.

Patients taking ambroxol are not recommended to perform breathing exercises due to difficulty in sputum discharge. In critically ill patients, aspiration of liquefied sputum should be performed.

You should not take ambroxol immediately before bed.

In patients with bronchial asthma, ambroxol may increase cough.

In patients with severe skin lesions – Stevens-Johnson syndrome or toxic epidermal necrolysis – a flu-like condition may be observed in the early phase: fever, body pain, rhinitis, cough, pharyngitis. During symptomatic therapy, it is possible to erroneously prescribe mucolytic drugs such as ambroxol hydrochloride.

Active ingredient

Ambroxol

Composition

5 ml of oral solution contains:

active ingredient:

ambroxol hydrochloride 30.00 mg;

excipients:

citric acid monohydrate 2.00 mg,

liquid sorbitol 70% 2250.00 mg,

glycerol 860.00 mg

methyl parahydroxybenzoate 6.00 mg,

propyl parahydroxybenzoate 1.5 mg,

propylene glycol 150.00 mg,

raspberry flavor 2.50 mg (for a dosage of 30 mg/5 ml),

purified water up to 5 ml.

Contraindications

hypersensitivity to ambroxol, bromhexine or other components of the drug;
hereditary fructose intolerance (due to the fact that the drug contains sorbitol);
Pregnancy (first trimester);
breastfeeding period;
children under 6 years of age (for a dose of 30 mg/5 ml);
In children under 2 years of age, the drug can only be used as prescribed by a doctor.
With caution
pregnancy (II-III trimester);
liver failure;
renal failure;
peptic ulcer of the stomach and duodenum in the acute stage;
impaired bronchial motor function and increased sputum production (with immotile cilia syndrome).

Side Effects

Allergic reactions: rarely – skin rash, urticaria, exanthema, facial swelling, shortness of breath, itching, fever; frequency unknown – anaphylactic reactions, including anaphylactic shock, angioedema, itching, allergic contact dermatitis.

From the digestive system: often – nausea; uncommon – vomiting, diarrhea, dyspepsia, abdominal pain.

From the nervous system: often – dysgeusia.

From the skin and subcutaneous tissues: very rarely – toxic epidermal necrolysis (Lyell’s syndrome), Stevens-Johnson syndrome; frequency unknown – acute generalized eczematous pustulosis.

From the respiratory system: often – decreased sensitivity in the mouth or pharynx; rarely – dryness of the mucous membrane of the respiratory tract, rhinorrhea; in isolated cases – dryness of the pharyngeal mucosa.

Interaction

Ambroxol should not be taken simultaneously with antitussives, due to the possible suppression of the cough reflex and retention of secretions in the respiratory tract.

Ambroxol should not be taken simultaneously with drugs that suppress bronchial secretions.

Ambroxol increases the penetration of certain antibiotics (for example, amoxicillin, cefuroxime, erythromycin, doxycycline) into the lung tissue and, therefore, increases their concentration in the lung parenchyma.

Overdose

Specific symptoms of overdose in humans have not been described. There have been reports of accidental overdose resulting in symptoms of known side effects of ambroxol: nausea, dyspepsia, diarrhea, vomiting, abdominal pain.

Treatment: artificial vomiting, gastric lavage in the first 1-2 hours after taking the drug, symptomatic therapy. Due to the high degree of binding of ambroxol to plasma proteins and the large volume of distribution, hemodialysis or forced diuresis is not advisable.

Recommendations for use

Inside, after eating.

The mucolytic effect of the drug occurs when taking large amounts of liquid. Therefore, drinking plenty of fluids is recommended during treatment. The drug should not be taken immediately before bedtime.

For dosing, use a teaspoon.

Adults and children over 12 years old

During the first 2-3 days, take 5 ml (30 mg) of the oral solution 3 times a day, then the dose should be reduced to 5 ml (30 mg) of the oral solution 2 times a day.

Children from 6 to 12 years old

2.5 ml (15 mg) solution for oral administration 2-3 times a day.

The maximum daily dose for adults is 120 mg ambroxol; the maximum daily dose for children from 6 to 12 years is 45 mg of ambroxol; the maximum daily dose for children from 2 to 6 years is 22.5 mg of ambroxol; the maximum daily dose for children under 2 years of age is 15 mg ambroxol.

The duration of treatment is determined individually depending on the course of the disease. It is not recommended to take ambroxol for more than 4-5 days without consulting a doctor.

Manufacturer

Vetprom AD, Bulgaria